Drugs / rAAV2/8-hCYP4V2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04722107 | Apr 2021 → Jan 2024 | Bietti crystalline corneoretinal dystrophy | Beijing Tongren Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2/8-hCYP4V2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04722107 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “rAAV2/8-hCYP4V2 Gene Replacement Therapy Drug Administered as a Single Subretinal Injection” NCT04722107 ↗ |